证券记录 · 已归档季度
OCUL
Ocular Therapeutix, Inc. · Healthcare · Biotechnology
18被追踪持有人
0Δ持有人
82.57M持有股份
$965.26M报告持仓市值
+1新建仓位
−1清仓
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 +30.0% · 净新建仓位 0.0% · 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 70.61K | $537,539 | n/a | n/a |
| Q2 2026 | 90 | -7 | 115.87M | $1.14B | +4 | −12 |
| Q1 2026 | 101 | +4 | 114.41M | $983.07M | +11 | −8 |
| Q4 2025 | 96 | +1 | 115.21M | $1.40B | +2 | n/a |
| Q3 2025 | 18 | 0 | 82.57M | $965.26M | +1 | −1 |
| Q2 2025 | 15 | +1 | 57.50M | $533.65M | +1 | n/a |
| Q1 2025 | 11 | 0 | 20.34M | $149.08M | +1 | −1 |
| Q4 2024 | 11 | +1 | 19.58M | $167.25M | +2 | −1 |
| Q3 2024 | 9 | +1 | 15.07M | $131.15M | +1 | n/a |
| Q2 2024 | 8 | n/a | 16.30M | $111.49M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 31.79M | +62.1% | $371.57M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (被动) | 10.56M | +0.1% | $123.41M | 0.0% | ▲ Add | 2 | SEC ↗ ×13 |
| 3 | The Vanguard Group ✦ (被动) | 9.16M | +9.2% | $107.12M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 4 | Citadel Advisors ✦ | 5.70M | +16.7% | $66.68M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | Point72 Asset Management ✦ | 4.60M | +141.6% | $53.79M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 4.00M | +2.9% | $46.81M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 7 | Millennium Management ✦ | 3.86M | +3136.1% | $45.07M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (被动) | 3.46M | -1.4% | $40.45M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Geode Capital Management ✦ (被动) | 3.34M | +1.6% | $39.03M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Morgan Stanley ✦ | 2.47M | n/a | $28.82M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 11 | Marshall Wace ✦ | 1.60M | 新增 | $18.72M | 0.0% | New | 1 | SEC ↗ ×3 |
| 12 | Goldman Sachs Group ✦ | 795.97K | n/a | $9.30M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 13 | JPMorgan Chase ✦ | 552.32K | n/a | $6.46M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 14 | Two Sigma Investments ✦ | 234.21K | +111.3% | $2.74M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 145.88K | +31.4% | $1.71M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 16 | T. Rowe Price ✦ | 131.56K | +4.1% | $1.54M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 113.28K | +10.2% | $1.32M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Wellington Management ✦ | 61.56K | -87.8% | $719,683 | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $18.72M | 0.0% |
已清仓
| Renaissance Technologies | $3.81M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 266 持有人, 206.22M 股份, $1.70B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 08
Anderman Todd
Officer · 11.98K 股 · $87,363
Oct 02
Heier Jeffrey S.
Officer · 10.87K 股 · $76,626
Oct 02
Kaiser Peter
Officer · 9.99K 股 · $70,430
Aug 24
Kaiser Peter
Officer · 3.04K 股 · $32,687
Aug 24
Heier Jeffrey S.
Officer · 3.30K 股 · $35,531
Aug 24
Dugel Pravin
Officer, Director · 21.65K 股 · $233,160
Aug 24
Nayak Sanjay
Officer · 1.90K 股 · $20,450
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Jul 29
SC 13G/A: BlackRock, Inc.
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据